Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRP-104 in NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer
NCT07249372Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirpiglenastat in non-small cell lung cancer (NSCLC), sponsored by NYU Langone Health. Started Jan 2026; status: recruiting.
02
Drugs
sirpiglenastat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07249372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07249372.